RareCyte Investors

29 investors on Angel Roster list RareCyte in their portfolio. Most are venture capital firms and private equity firms, the most common stage is Seed and the largest groups are based in the United States.

Investors are matched on the company name in their portfolio, so companies that share the name RareCyte can appear together.

Investors listed
29
With verified email
45%
Most common stage
Seed
Top location
United States

Updated October 13, 2026 · How we compile this data

Top 29 RareCyte investors

The most complete profiles first. Showing 29 of 29.

  • Andy SchwabVerified

    Venture Capital, Founder, Private Equity Firm · United States

    SeedHealth CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 57 more

    Verified email available

  • Brian DanielsVerified

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Verified email available

  • David KabakoffVerified

    Venture Capital, Private Equity Firm, Investor · United States

    Series BHealth CareCybersecurityMessagingWellness

    Portfolio: Magnolia Medical Technologies, Avizia, RareCyte, inMediata and 22 more

    Verified email available

  • Deborah PalestrantVerified

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Verified email available

  • Garheng KongVerified

    Venture Capital, Private Equity Firm, Investor · United States

    Series BHealth CareCybersecurityMessagingWellness

    Portfolio: Magnolia Medical Technologies, Avizia, RareCyte, inMediata and 20 more

    Verified email available

  • Gary CurtisVerified

    Venture Capital, Private Equity Firm, Angel/Individual · United States

    SeedHealth CareHospitalsGeneticsAndroid

    Portfolio: Precision NanoSystem, TrakCel, Nimble Therapeutics, Estech and 18 more

    Verified email available

  • Jared TeoVerified

    Venture Capital, Private Equity Firm, Investor · United States

    Series BHealth CareCybersecurityMessagingWellness

    Portfolio: Magnolia Medical Technologies, Avizia, RareCyte, inMediata and 20 more

    Contact details available

  • Jason RuthVerified

    Venture Capital, Investor · United States

    SeedHealth CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Verified email available

  • Lou TartagliaVerified

    Venture Capital, Founder, Investor · United States

    SeedHealth CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 53 more

    Verified email available

  • Rebecca ChenVerified

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Verified email available

  • Robert SheplerVerified

    Venture Capital, Founder, Private Equity Firm · United States

    SeedHealth CareGeneticsChemicalLife Science

    Portfolio: Precision NanoSystem, TrakCel, Nimble Therapeutics, Estech and 18 more

    Verified email available

  • Elliot EhrichVerified

    Venture Capital · United States

    Health CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Contact details available

  • Jan GarfinkleVerified

    Venture Capital, Private Equity Firm · United States

    Series BSeries AHealth CareHospitalsWellnessWomen Founded

    Portfolio: Koya Medical, RareCyte, NxThera, Francis Medical and 4 more

    Verified email available

  • Jonathan WeissmanVerified

    Venture Capital · United States

    Health CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Contact details available

  • Paul GrossmanVerified

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsAndroidChemical

    Portfolio: Precision NanoSystem, TrakCel, Nimble Therapeutics, Estech and 18 more

    Verified email available

  • Paul StoneVerified

    Venture Capital · United States

    Health CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Verified email available

  • Deval Lashkari

    Venture Capital, Private Equity Firm, Investor · United States

    SeedPre-SeedHealth CareGeneticsAndroidChemical

    Portfolio: Precision NanoSystem, TrakCel, Nimble Therapeutics, Estech and 19 more

    Contact details available

  • Jamil M. Beg

    Venture Capital, Investor · United States

    SeedHealth CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Contact details available

  • Jeanette Welsh

    Venture Capital, Private Equity Firm, Angel/Individual · United States

    SeedHealth CareGeneticsAndroidChemical

    Portfolio: Precision NanoSystem, TrakCel, Nimble Therapeutics, Estech and 18 more

    Contact details available

  • John Diekman

    Venture Capital, Founder, Private Equity Firm · United States

    SeedHealth CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 53 more

    Contact details available

  • Mason Freeman

    Venture Capital, Investor · United States

    SeedHealth CareHospitalsGeneticsLife Science

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Contact details available

  • Mira Chaurushiya

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareGeneticsAlternative MedicineAndroid

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Contact details available

  • Scott Rocklage

    Venture Capital, Founder, Private Equity Firm · United States

    SeedHealth CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 53 more

    Contact details available

  • Todd Creech

    Venture Capital, Private Equity Firm, Investor · United States

    Series BHealth CareCybersecurityMessagingWellness

    Portfolio: Magnolia Medical Technologies, Avizia, RareCyte, inMediata and 20 more

    Contact details available

  • Victoria Lai

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareCybersecurityMessagingWellness

    Portfolio: Magnolia Medical Technologies, Avizia, RareCyte, inMediata and 20 more

    Contact details available

  • Joseph Victor

    Venture Capital · United States

    Health CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Contact details available

  • Peter Kim

    Venture Capital · United States

    Health CareGeneticsLife ScienceSoftware

    Portfolio: Precision NanoSystem, Vor Biopharma, Aprea, Arvinas and 52 more

    Contact details available

  • Trit Garg

    Venture Capital, Private Equity Firm · United States

    Health CareCybersecurityMessagingWellness

    Portfolio: Magnolia Medical Technologies, Avizia, RareCyte, inMediata and 20 more

    Contact details available

  • Ron Seubert

    Angel/Individual · United States

    SeedHealth CareBiotechnologyHealth DiagnosticsMedical

    Portfolio: RareCyte

    Contact details available

By investment stage

By location

Related industries

Most-backed portfolio companies

Frequently asked questions

How many RareCyte investors are on Angel Roster?

Angel Roster lists 29 RareCyte investors. 13 of them (45%) include a verified email address.

What types of investors are they?

The most common investor types are Venture Capital Firms (28), Private Equity Firms (19) and Founder-Investors (5). An investor can have more than one type, for example an angel who is also a venture partner.

Which stages do RareCyte investors invest in?

Among those that list a stage, the most common are Seed (17), Series B (5) and Pre-Seed (1).

Where are RareCyte investors based?

Most are based in the United States (29).

Which companies have RareCyte investors backed?

The most-backed portfolio companies among them are Precision NanoSystem (21), Cleave Therapeutics (16), Calibrium (16), Viveve (16) and Bellerophon Therapeutics (16).

How do I contact RareCyte investors?

Create a free Angel Roster account to search and filter all 29, then unlock verified emails and LinkedIn profiles on a paid plan. Every plan starts with a 3-day free trial.